Data / Drug companies / Kinase Inhibitor
Kinase Inhibitor drugs: 78 drugs from 113 companies in the FDA NDC directory
Kinase Inhibitor is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 596 products in this class from 113 companies, covering 78 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on November 2, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 113Companies
- 596Products
- 78Drugs by generic name
Drugs in the Kinase Inhibitor class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Sirolimus | 40 | 22 |
| Dasatinib | 108 | 18 |
| Imatinib mesylate | 36 | 17 |
| Everolimus | 81 | 15 |
| Nintedanib | 22 | 11 |
| Nilotinib | 25 | 10 |
| Sunitinib malate | 36 | 9 |
| Sorafenib | 9 | 8 |
| Pazopanib | 6 | 6 |
| Erlotinib | 15 | 5 |
| Bosutinib | 11 | 5 |
| Gefitinib | 5 | 5 |
| Erlotinib hydrochloride | 12 | 4 |
| Imatinib | 8 | 4 |
| Lapatinib | 4 | 4 |
| Pazopanib hydrochloride | 3 | 3 |
| Palbociclib | 9 | 2 |
| Larotrectinib | 7 | 2 |
| Afatinib | 6 | 2 |
| Axitinib | 4 | 2 |
| Lorlatinib | 3 | 2 |
| Ritlecitinib | 2 | 2 |
| Trilaciclib | 2 | 2 |
| Ruxolitinib | 11 | 1 |
| Ibrutinib | 6 | 1 |
| Selpercatinib | 6 | 1 |
| Avapritinib | 5 | 1 |
| Crizotinib | 5 | 1 |
| Lenvatinib | 5 | 1 |
| Abemaciclib | 4 | 1 |
| Cabozantinib | 4 | 1 |
| Everolimus tablets | 4 | 1 |
| Osimertinib | 4 | 1 |
| Ponatinib hydrochloride | 4 | 1 |
| Selumetinib | 4 | 1 |
| Acalabrutinib | 3 | 1 |
| Brigatinib | 3 | 1 |
| Cabozantinib laurylsulfate | 3 | 1 |
| Dabrafenib | 3 | 1 |
| Erdafitinib | 3 | 1 |
| Leniolisib | 3 | 1 |
| Mirdametinib | 3 | 1 |
| Momelotinib | 3 | 1 |
| Pemigatinib | 3 | 1 |
| Ribociclib | 3 | 1 |
| Trametinib | 3 | 1 |
| Vimseltinib | 3 | 1 |
| Capmatinib | 2 | 1 |
| Futibatinib | 2 | 1 |
| Idelalisib | 2 | 1 |
| Inavolisib | 2 | 1 |
| Lazertinib | 2 | 1 |
| Nintedanib esylate | 2 | 1 |
| Pirtobrutinib | 2 | 1 |
| Quizartinib | 2 | 1 |
| Repotrectinib | 2 | 1 |
| Tivozanib | 2 | 1 |
| Tucatinib | 2 | 1 |
| Vandetanib | 2 | 1 |
| Zanubrutinib | 2 | 1 |
| Alectinib hydrochloride | 1 | 1 |
| Ceritinib | 1 | 1 |
| Cobimetinib | 1 | 1 |
| Gedatolisib | 1 | 1 |
| Imatinib oral | 1 | 1 |
| Neratinib | 1 | 1 |
| Pacritinib | 1 | 1 |
| Pexidartinib hydrochloride | 1 | 1 |
| Pralsetinib | 1 | 1 |
| Regorafenib | 1 | 1 |
| Remibrutinib | 1 | 1 |
| Ripretinib | 1 | 1 |
| Rydapt | 1 | 1 |
| Taletrectinib | 1 | 1 |
| Tepotinib hydrochloride | 1 | 1 |
| Tovorafenib | 1 | 1 |
| Vemurafenib | 1 | 1 |
| Zongertinib | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 33 | tablet; tablet, film coated | New drug applications (NDA) | September 30, 2025 |
| Pfizer Laboratories Div Pfizer Inc | 25 | capsule; tablet, film coated | New drug applications (NDA) | January 2, 2024 |
| Aurobindo Pharma Limited | 20 | tablet; tablet, film coated | Generic drugs (ANDA) | February 25, 2026 |
| Biocon Pharma Inc. | 17 | tablet; tablet, film coated | Generic drugs (ANDA) | January 14, 2026 |
| Novadoz Pharmaceuticals LLC | 17 | capsule; tablet | Generic drugs (ANDA) | September 11, 2026 |
| Dr. Reddy's Laboratories Inc. | 16 | capsule; tablet, film coated | Generic drugs (ANDA) | April 2, 2026 |
| Apotex Corp. | 15 | tablet, film coated; capsule | Generic drugs (ANDA) | April 2, 2026 |
| Incyte Corporation | 14 | tablet; tablet, extended release | New drug applications (NDA) | May 1, 2026 |
| AstraZeneca Pharmaceuticals LP | 12 | tablet, film coated; capsule | New drug applications (NDA) | September 10, 2025 |
| Eli Lilly and Company | 12 | tablet, coated; tablet | New drug applications (NDA) | April 10, 2024 |
| Alembic Pharmaceuticals Inc. | 11 | tablet, film coated | Generic drugs (ANDA) | May 19, 2026 |
| Alembic Pharmaceuticals Limited | 11 | tablet, film coated | Generic drugs (ANDA) | May 19, 2026 |
| Breckenridge Pharmaceutical, Inc. | 11 | tablet; tablet, for suspension | Generic drugs (ANDA) | October 30, 2025 |
| Camber Pharmaceuticals, Inc. | 11 | tablet, film coated; capsule | Generic drugs (ANDA) | July 14, 2026 |
| NorthStar RxLLC | 11 | tablet, film coated; tablet | Generic drugs (ANDA) | June 1, 2026 |
| AvKARE | 10 | tablet, film coated; capsule | Generic drugs (ANDA) | July 21, 2026 |
| BluePoint Laboratories | 10 | tablet, film coated | Generic drugs (ANDA) | December 5, 2025 |
| Teva Pharmaceuticals, Inc. | 10 | tablet, film coated | Generic drugs (ANDA) | September 18, 2025 |
| Ascend Laboratories, LLC | 9 | tablet, film coated; tablet | Generic drugs (ANDA) | November 27, 2021 |
| Novugen Pharma (USA) LLC | 9 | capsule; tablet | Generic drugs (ANDA) | March 30, 2026 |
| Teva Pharmaceuticals USA, Inc. | 9 | tablet, film coated; capsule | Generic drugs (ANDA) | December 22, 2021 |
| Zydus Lifesciences Limited | 9 | tablet; tablet, film coated | Generic drugs (ANDA) | March 3, 2025 |
| Cycle Pharmaceuticals Ltd | 8 | tablet; tablet, orally disintegrating | New drug applications (NDA) | June 30, 2026 |
| E.r. Squibb & Sons, L.L.C. | 8 | tablet; capsule | New drug applications (NDA) | November 1, 2024 |
| Hikma Pharmaceuticals USA Inc. | 8 | tablet | Generic drugs (ANDA) | November 18, 2021 |
| Natco Pharma Limited | 8 | tablet | Generic drugs (ANDA) | October 1, 2021 |
| Quallent Pharmaceuticals Health LLC | 8 | tablet, film coated | Generic drugs (ANDA) | November 2, 2026 |
| U.S. Pharmaceuticals | 8 | tablet, film coated; capsule | New drug applications (NDA) | July 6, 2023 |
| Bayer HealthCare Pharmaceuticals Inc. | 7 | tablet, film coated; capsule | New drug applications (NDA) | October 2, 2023 |
| Mylan Pharmaceuticals Inc. | 7 | capsule; tablet, film coated | Generic drugs (ANDA) | June 1, 2022 |
| Takeda Pharmaceuticals America, Inc. | 7 | tablet, film coated | New drug applications (NDA) | January 11, 2021 |
| AvKARE | 6 | capsule; tablet, film coated | Generic drugs (ANDA) | March 12, 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | tablet, film coated; capsule | New drug applications (NDA) | August 8, 2025 |
| CivicaScript LLC | 6 | tablet; tablet, film coated | Generic drugs (ANDA) | July 3, 2026 |
| Golden State Medical Supply, Inc. | 6 | tablet, film coated; capsule | Generic drugs (ANDA) | February 15, 2026 |
| Lupin Pharmaceuticals, Inc. | 6 | tablet | Generic drugs (ANDA) | January 30, 2026 |
| Pharmacyclics LLC | 6 | tablet, film coated; capsule | New drug applications (NDA) | August 24, 2022 |
| Prasco Laboratories | 6 | tablet | Authorized generics (NDA) | September 3, 2024 |
| Zydus Pharmaceuticals USA Inc. | 6 | tablet | Generic drugs (ANDA) | March 3, 2025 |
| Zydus Pharmaceuticals USA Inc. | 6 | tablet, film coated; tablet | Generic drugs (ANDA) | February 16, 2023 |
| Armas Pharmaceuticals Inc. | 5 | tablet, film coated | Generic drugs (ANDA) | November 6, 2019 |
| Blueprint Medicines Corporation | 5 | tablet, film coated | New drug applications (NDA) | June 16, 2021 |
| Cipla USA Inc. | 5 | capsule | New drug applications (NDA) | April 2, 2026 |
| Eisai Inc. | 5 | capsule | New drug applications (NDA) | August 15, 2018 |
| Genentech, Inc. | 5 | tablet, film coated; capsule | New drug applications (NDA) | October 14, 2024 |
| Glenmark Pharmaceuticals Inc., USA | 5 | tablet, film coated; capsule | Generic drugs (ANDA) | July 9, 2026 |
| Sun Pharmaceutical Industries, Inc. | 5 | capsule; tablet, film coated | Generic drugs (ANDA) | October 20, 2023 |
| Deciphera Pharmaceuticals, LLC | 4 | capsule; tablet | New drug applications (NDA) | February 14, 2025 |
| Exelixis, Inc. | 4 | tablet; capsule | New drug applications (NDA) | April 25, 2016 |
| I3 Pharmaceuticals, LLC | 4 | tablet | Generic drugs (ANDA) | August 7, 2026 |
| Mylan Pharmaceuticals Inc. | 4 | tablet, sugar coated; solution | Authorized generics (NDA) | July 22, 2019 |
| Remedyrepack Inc. | 4 | tablet; tablet, film coated | Generic drugs (ANDA) | August 19, 2025 |
| Torrent Pharmaceuticals Limited | 4 | capsule; tablet, film coated | Generic drugs (ANDA) | December 16, 2025 |
| Upsher-Smith Laboratories, LLC | 4 | tablet | Generic drugs (ANDA) | October 1, 2021 |
| Amneal Pharmaceuticals NY LLC | 3 | tablet, for suspension | Generic drugs (ANDA) | January 14, 2025 |
| Ani Pharmaceuticals, Inc. | 3 | tablet, for suspension | Generic drugs (ANDA) | October 10, 2025 |
| Daiichi Sankyo Inc. | 3 | tablet, film coated; capsule | New drug applications (NDA) | July 20, 2023 |
| GlaxoSmithKline LLC | 3 | tablet | New drug applications (NDA) | September 15, 2023 |
| Handa Pharma | 3 | capsule | New drug applications (NDA) | November 1, 2026 |
| Janssen Products, LP | 3 | tablet, film coated | New drug applications (NDA) | April 12, 2019 |
| Loxo Oncology, Inc. | 3 | capsule; solution | New drug applications (NDA) | November 26, 2018 |
| Major Pharmaceuticals | 3 | tablet, film coated | Generic drugs (ANDA) | March 13, 2021 |
| NorthStar Rx LLC | 3 | tablet, film coated | Generic drugs (ANDA) | October 18, 2021 |
| Pharming Healthcare Inc. | 3 | tablet, film coated | New drug applications (NDA) | September 11, 2026 |
| Qilu Pharmaceutical Co., Ltd. | 3 | tablet; tablet, coated | Generic drugs (ANDA) | February 13, 2023 |
| SpringWorks Therapeutics, Inc. | 3 | capsule; tablet, for suspension | New drug applications (NDA) | February 11, 2025 |
| Zydus Lifesciences Limited | 3 | tablet, film coated | Generic drugs (ANDA) | February 16, 2023 |
| American Health Packaging | 2 | tablet, film coated | Generic drugs (ANDA) | June 2, 2026 |
| Archis Pharma LLC | 2 | tablet | Generic drugs (ANDA) | September 1, 2022 |
| AvPAK | 2 | tablet; tablet, film coated | Generic drugs (ANDA) | October 27, 2026 |
| Aveo Pharmaceuticals, Inc. | 2 | capsule | New drug applications (NDA) | March 10, 2021 |
| Azurity Pharmaceuticals, Inc. | 2 | tablet | New drug applications (NDA) | November 30, 2024 |
| BeOne Medicines USA, Inc. | 2 | tablet, film coated; capsule | New drug applications (NDA) | August 18, 2025 |
| Chartwell RX, LLC | 2 | tablet, film coated | Generic drugs (ANDA) | January 17, 2019 |
| Dr. Reddy's Laboratories Limited | 2 | tablet | Generic drugs (ANDA) | October 27, 2014 |
| Edenbridge Pharmaceuticals LLC. | 2 | capsule | Generic drugs (ANDA) | April 3, 2026 |
| Epic Pharma, LLC | 2 | capsule | Generic drugs (ANDA) | July 9, 2026 |
| Exelan Pharmaceuticals Inc. | 2 | capsule | Generic drugs (ANDA) | May 7, 2026 |
| Genzyme Corporation | 2 | tablet, film coated | New drug applications (NDA) | July 25, 2011 |
| Gilead Sciences, Inc. | 2 | tablet, film coated | New drug applications (NDA) | July 23, 2014 |
| Janssen Biotech, Inc. | 2 | tablet, film coated | New drug applications (NDA) | August 20, 2024 |
| Macleods Pharmaceuticals Limited | 2 | capsule | Generic drugs (ANDA) | August 3, 2026 |
| Mylan Institutional Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | September 7, 2017 |
| Par Health USA, LLC | 2 | tablet | Generic drugs (ANDA) | March 31, 2022 |
| Safecor Health, LLC | 2 | tablet, film coated | Generic drugs (ANDA) | April 10, 2026 |
| Sandoz Inc | 2 | capsule | Generic drugs (ANDA) | April 2, 2026 |
| Seagen Inc. | 2 | tablet | New drug applications (NDA) | April 17, 2020 |
| Sun Pharmaceutical Industries, Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | February 1, 2016 |
| Taiho Pharmaceutical Co., LTD. | 2 | tablet | New drug applications (NDA) | June 1, 2026 |
| Upsher-Smith Laboratories, LLC | 2 | tablet | Generic drugs (ANDA) | May 17, 2024 |
| Aadi Bioscience, Inc. | 1 | injection, powder, lyophilized, for suspension | New drug applications (NDA) | December 6, 2021 |
| American Health Packaging | 1 | tablet | Generic drugs (ANDA) | November 5, 2015 |
| Amneal Pharmaceuticals NY LLC | 1 | solution | Generic drugs (ANDA) | October 25, 2019 |
| Bryant Ranch Prepack | 1 | solution | Generic drugs (ANDA) | January 19, 2023 |
| Celcuity Inc. | 1 | injection, powder, for solution | New drug applications (NDA) | September 30, 2026 |
| Day One Biopharmaceuticals, Inc. | 1 | tablet, film coated | New drug applications (NDA) | April 30, 2024 |
| Dr. Reddy's Laboratories Inc. | 1 | tablet, film coated | Generic drugs (ANDA) | June 12, 2026 |
| Emd Serono, Inc. | 1 | tablet | New drug applications (NDA) | February 3, 2021 |
| G1 Therapeutics, Inc. | 1 | injection, powder, lyophilized, for solution | New drug applications (NDA) | February 12, 2021 |
| Ingenus Pharmaceuticals, LLC | 1 | tablet, coated | Generic drugs (ANDA) | April 27, 2023 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 238 | 39.9% |
| Tablet | 168 | 28.2% |
| Capsule | 126 | 21.1% |
| Tablet, for suspension | 17 | 2.9% |
| Solution | 11 | 1.8% |
| Tablet, coated | 9 | 1.5% |
| Tablet, extended release | 5 | 0.8% |
| Tablet, sugar coated | 3 | 0.5% |
| Capsule, coated pellets | 3 | 0.5% |
| Tablet, orally disintegrating | 2 | 0.3% |
| Granule | 2 | 0.3% |
| Solution, concentrate | 2 | 0.3% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.